File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus

TitleMolecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus
Authors
Issue Date2010
PublisherAmerican Society for Microbiology. The Journal's web site is located at http://jvi.asm.org/
Citation
Journal Of Virology, 2010, v. 84 n. 17, p. 8369-8388 How to Cite?
Abstract
The 2009 H1N1 influenza pandemic has prompted a significant need for the development of efficient, single-dose, adjuvanted vaccines. Here we investigated the adjuvant potential of CpG oligodeoxynucleotide (ODN) when used with a human seasonal influenza virus vaccine in ferrets. We found that the CpG ODNadjuvanted vaccine effectively increased antibody production and activated type I interferon (IFN) responses compared to vaccine alone. Based on these findings, pegylated IFN-α2b (PEG-IFN) was also evaluated as an adjuvant in comparison to CpG ODN and complete Freund's adjuvant (CFA). Our results showed that all three vaccines with adjuvant added prevented seasonal human A/Brisbane/59/2007 (H1N1) virus replication more effectively than did vaccine alone. Gene expression profiles indicated that, as well as upregulating IFN-stimulated genes (ISGs), CpG ODN enhanced B-cell activation and increased Toll-like receptor 4 (TLR4) and IFN regulatory factor 4 (IRF4) expression, whereas PEG-IFN augmented adaptive immunity by inducing major histocompatibility complex (MHC) transcription and Ras signaling. In contrast, the use of CFA as an adjuvant induced limited ISG expression but increased the transcription of MHC, cell adhesion molecules, and B-cell activation markers. Taken together, our results better characterize the specific molecular pathways leading to adjuvant activity in different adjuvant-mediated influenza virus vaccinations. Copyright © 2010, American Society for Microbiology. All Rights Reserved.
Persistent Identifierhttp://hdl.handle.net/10722/125150
ISSN
2013 Impact Factor: 4.648
PubMed Central ID
ISI Accession Number ID
Funding AgencyGrant Number
Li Ka Shing Foundation
Canadian Institute of Health Research
Sardegna Ricerche
National Institutes of Health
Funding Information:

This work is supported by grants from the Li Ka Shing Foundation, the Canadian Institute of Health Research, Sardegna Ricerche, and the National Institutes of Health.

References

 

Author Affiliations
  1. Toronto General Research Institute University of Toronto
  2. Università degli Studi di Sassari
  3. Shantou University, Medical College (SUMC)
  4. University of Pennsylvania
  5. University of Toronto
DC FieldValueLanguage
dc.contributor.authorFang, Yen_HK
dc.contributor.authorRowe, Ten_HK
dc.contributor.authorLeon, AJen_HK
dc.contributor.authorBanner, Den_HK
dc.contributor.authorDanesh, Aen_HK
dc.contributor.authorXu, Len_HK
dc.contributor.authorRan, Len_HK
dc.contributor.authorBosinger, SEen_HK
dc.contributor.authorGuan, Yen_HK
dc.contributor.authorChen, Hen_HK
dc.contributor.authorCameron, CCen_HK
dc.contributor.authorCameron, MJen_HK
dc.contributor.authorKelvin, DJen_HK
dc.date.accessioned2010-10-31T11:14:14Z-
dc.date.available2010-10-31T11:14:14Z-
dc.date.issued2010en_HK
dc.identifier.citationJournal Of Virology, 2010, v. 84 n. 17, p. 8369-8388en_HK
dc.identifier.issn0022-538Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/125150-
dc.description.abstractThe 2009 H1N1 influenza pandemic has prompted a significant need for the development of efficient, single-dose, adjuvanted vaccines. Here we investigated the adjuvant potential of CpG oligodeoxynucleotide (ODN) when used with a human seasonal influenza virus vaccine in ferrets. We found that the CpG ODNadjuvanted vaccine effectively increased antibody production and activated type I interferon (IFN) responses compared to vaccine alone. Based on these findings, pegylated IFN-α2b (PEG-IFN) was also evaluated as an adjuvant in comparison to CpG ODN and complete Freund's adjuvant (CFA). Our results showed that all three vaccines with adjuvant added prevented seasonal human A/Brisbane/59/2007 (H1N1) virus replication more effectively than did vaccine alone. Gene expression profiles indicated that, as well as upregulating IFN-stimulated genes (ISGs), CpG ODN enhanced B-cell activation and increased Toll-like receptor 4 (TLR4) and IFN regulatory factor 4 (IRF4) expression, whereas PEG-IFN augmented adaptive immunity by inducing major histocompatibility complex (MHC) transcription and Ras signaling. In contrast, the use of CFA as an adjuvant induced limited ISG expression but increased the transcription of MHC, cell adhesion molecules, and B-cell activation markers. Taken together, our results better characterize the specific molecular pathways leading to adjuvant activity in different adjuvant-mediated influenza virus vaccinations. Copyright © 2010, American Society for Microbiology. All Rights Reserved.en_HK
dc.languageengen_HK
dc.publisherAmerican Society for Microbiology. The Journal's web site is located at http://jvi.asm.org/en_HK
dc.relation.ispartofJournal of Virologyen_HK
dc.rightsJournal of Virology. Copyright © American Society for Microbiology.-
dc.rightsCopyright © American Society for Microbiology, Journal of Virology, 2010, v. 84 n. 17, p. 8369-8688-
dc.subject.meshFerrets-
dc.subject.meshInfluenza A Virus, H1N1 Subtype - genetics - immunology - physiology-
dc.subject.meshInfluenza Vaccines - administration and dosage - genetics - immunology-
dc.subject.meshInfluenza, Human - immunology - prevention and control - virology-
dc.subject.meshOligodeoxyribonucleotides - administration and dosage - immunology-
dc.titleMolecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virusen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0022-538X&volume=84&issue=17&spage=8369&epage=8688&date=2010&atitle=Molecular+characterization+of+in+vivo+adjuvant+activity+in+influenza-vaccinated+ferrets+-
dc.identifier.emailGuan, Y: yguan@hkucc.hku.hken_HK
dc.identifier.emailChen, H: hlchen@hku.hken_HK
dc.identifier.authorityGuan, Y=rp00397en_HK
dc.identifier.authorityChen, H=rp00383en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1128/JVI.02305-09en_HK
dc.identifier.pmid20534862-
dc.identifier.pmcidPMC2919000-
dc.identifier.scopuseid_2-s2.0-77956642388en_HK
dc.identifier.hkuros180506en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77956642388&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume84en_HK
dc.identifier.issue17en_HK
dc.identifier.spage8369en_HK
dc.identifier.epage8388en_HK
dc.identifier.isiWOS:000280605300002-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridFang, Y=35745989100en_HK
dc.identifier.scopusauthoridRowe, T=7102561610en_HK
dc.identifier.scopusauthoridLeon, AJ=14062184100en_HK
dc.identifier.scopusauthoridBanner, D=23092848400en_HK
dc.identifier.scopusauthoridDanesh, A=10639081200en_HK
dc.identifier.scopusauthoridXu, L=7404744742en_HK
dc.identifier.scopusauthoridRan, L=7006581232en_HK
dc.identifier.scopusauthoridBosinger, SE=6507734312en_HK
dc.identifier.scopusauthoridGuan, Y=7202924055en_HK
dc.identifier.scopusauthoridChen, H=26643315400en_HK
dc.identifier.scopusauthoridCameron, CC=55434453200en_HK
dc.identifier.scopusauthoridCameron, MJ=7102724879en_HK
dc.identifier.scopusauthoridKelvin, DJ=7006326577en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats